Literature DB >> 12065729

Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration.

Kent W Christopherson1, James J Campbell, Jeffrey B Travers, Robert A Hromas.   

Abstract

The chemokine CCL21, also known as Exodus-2/6-Ckine/secondary lymphoid-tissue chemokine/T cell activator protein-4, is the most potent stimulator of T cell migration and adhesion yet described. Endothelial heparin-like glycosaminoglycans (GAGs) are thought to present chemokines at sites of inflammation, maintaining a local concentration gradient to which leukocytes can respond. In contrast, this study found that GAGs markedly inhibit the ability of CCL21 to stimulate T cell adhesion and chemotaxis. Enzymes, such as heparinase, that split GAGs into component-sulfated saccharides abrogate this inhibition, suggesting a mechanism for local tissue regulation of CCL21 function. Low-molecular-weight heparins also strongly inhibit CCL21 adhesion and chemotaxis. Therefore, low-molecular-weight heparins may be effective therapeutic agents in decreasing the pathology of T cell-infiltrative autoimmune diseases by targeting the CCL21 regulation of T cell infiltration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065729     DOI: 10.1124/jpet.302.1.290

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Microfluidic device for studying cell migration in single or co-existing chemical gradients and electric fields.

Authors:  Jing Li; Ling Zhu; Michael Zhang; Francis Lin
Journal:  Biomicrofluidics       Date:  2012-05-16       Impact factor: 2.800

Review 2.  The role of FOXO1 in the decidual transformation of the endometrium and early pregnancy.

Authors:  Takeshi Kajihara; Jan J Brosens; Osamu Ishihara
Journal:  Med Mol Morphol       Date:  2013-02-05       Impact factor: 2.309

3.  Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres.

Authors:  Yana Wang; Darrell J Irvine
Journal:  Biomaterials       Date:  2011-04-03       Impact factor: 12.479

4.  Role of parnaparin in atherosclerosis.

Authors:  Francesca Bonomini; Samanta Taurone; Pierpaolo Parnigotto; Loris Zamai; Luigi F Rodella; Marco Artico; Rita Rezzani
Journal:  Int J Exp Pathol       Date:  2017-02-16       Impact factor: 1.925

Review 5.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 6.  Aspirin vs Heparin for the Prevention of Preeclampsia.

Authors:  Vasiliki Katsi; Theoni Kanellopoulou; Thomas Makris; Petros Nihoyannopoulos; Efrosyni Nomikou; Dimitrios Tousoulis
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

7.  The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity.

Authors:  Monika Pruenster; Liesbeth Mudde; Paula Bombosi; Svetla Dimitrova; Marion Zsak; Jim Middleton; Ann Richmond; Gerard J Graham; Stephan Segerer; Robert J B Nibbs; Antal Rot
Journal:  Nat Immunol       Date:  2008-12-07       Impact factor: 25.606

8.  Wound Healing Versus Regeneration: Role of the Tissue Environment in Regenerative Medicine.

Authors:  Anthony Atala; Darrell J Irvine; Marsha Moses; Sunil Shaunak
Journal:  MRS Bull       Date:  2010-08-01       Impact factor: 6.578

9.  Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia.

Authors:  Julie Catusse; Marion Leick; Mareike Groch; David J Clark; Maike V Buchner; Katja Zirlik; Meike Burger
Journal:  Mol Cancer       Date:  2010-11-22       Impact factor: 27.401

10.  Convolution of chemoattractant secretion rate, source density, and receptor desensitization direct diverse migration patterns in leukocytes.

Authors:  Yana Wang; Darrell J Irvine
Journal:  Integr Biol (Camb)       Date:  2013-03       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.